What stimulants are used in neurocritical care?

Stimulants Used in Neurocritical Care

The primary stimulants used in neurocritical care are amantadine, methylphenidate, and modafinil, with amantadine having the strongest evidence base for accelerating recovery in disorders of consciousness after acute brain injury.

Primary Pharmacologic Agents

Amantadine (First-Line)

• Most robust evidence for use in neurocritical care settings 1, 2
• Typically initiated at 100 mg twice daily 3
• Started median 7 days post-injury (range 1-27 days) 3
• Primary indications: somnolence, not following commands, lack of eye opening, low Glasgow Coma Scale 3
• Response typically seen within 3 days of initiation 3
• Most common adverse effect: sleep disruption (16% of patients) 3
• 88% of survivors continued on amantadine at hospital discharge, indicating sustained benefit 3

Methylphenidate (Second-Line)

• Dosing: 0.3 mg/kg per dose twice daily 4
• Can be initiated as early as day 2 of admission 4
• Demonstrated 23% reduction in ICU length of stay in severe TBI (p=0.06 for ICU, p=0.029 for hospital stay) 4
• In moderate TBI: 26% reduction in ICU stay (p=0.05) 4
• Starting dose in mixed populations: 100 mg twice daily (though 54% received this dose) 3
• Clinical arousal improvements noted in 9.96 times higher odds compared to placebo 5

Modafinil (Alternative Agent)

• Common starting dose: 100 mg twice daily (54% of patients) 3
• Limited monotherapy efficacy - no patients on modafinil alone were considered responders in one study 3
• May be more effective when combined with amantadine 3
• Positive evidence exists but is more limited than amantadine 2

Clinical Application Algorithm

Initiation Criteria

Start stimulants when patients demonstrate:

1. Persistent somnolence (77% of cases) 3
2. Not following commands (32%) 3
3. Lack of eye opening (28%) 3
4. Low GCS score (17%) 3

Treatment Sequence

1. Start with amantadine 100 mg twice daily as first-line agent
2. Assess response within 3-5 days using:
   • GCS improvement ≥3 points from baseline
   • Improved wakefulness documented in nursing notes
   • Clinical improvement in therapy participation 3
3. If inadequate response, consider adding methylphenidate (not switching to modafinil monotherapy)
4. Patients with greater pupillary responsiveness are more likely to respond to stimulants 5

Supporting Evidence for Other Agents

Dopaminergic Agents

• Bromocriptine and levodopa have supporting evidence but less robust than amantadine 1, 2

Acetylcholinesterase Inhibitors

• Donepezil and rivastigmine mentioned for cognitive enhancement 1
• Evidence less established in acute neurocritical care phase

Selective Serotonin Reuptake Inhibitors

• Citalopram has positive evidence for post-stroke recovery 2
• Sertraline and fluoxetine may improve mood and rehabilitation participation 1

Critical Caveats

Safety Considerations

• No significant adverse events directly related to amantadine or methylphenidate in ICU trials 5
• Sleep disruption is the most common side effect (16%) 3
• Both drugs demonstrated good safety profiles even when initiated early (day 1-2 post-injury) 4

Response Predictors

• Pupillary responsiveness predicts stimulant efficacy - patients with greater baseline pupillary responses show better arousal 5
• Responders were more frequently discharged home or to acute rehabilitation (90% vs 62%, p=0.006) 3

Timing Considerations

• Median initiation: 7 days post-stroke in mixed populations 3
• Can be started as early as day 2 in TBI patients 4
• Response typically occurs within 3 days (median 2-5 days) 3

Evidence Quality Note

The evidence base consists primarily of retrospective studies and small randomized trials 1, 5, 3. Amantadine remains the only neuromodulator with moderate-quality guideline support for disorders of consciousness 1. Current research is limited by heterogeneous populations, small sample sizes, and inconsistent outcome measures 1. However, the consistent safety profile and potential benefits support their use in carefully selected neurocritical care patients.